Drug Profile
Valbenazine - Neurocrine Biosciences
Alternative Names: DYSVAL; DYSVAL capsules 40mg; INGREZZA; MT 5199; NBI-98854; REMLEAS; Valbenazine-tosylate; VMAT2-inhibtor-Neurocrine-BiosciencesLatest Information Update: 19 Mar 2024
Price :
$50
*
At a glance
- Originator Neurocrine Biosciences
- Developer Mitsubishi Tanabe Pharma Corporation; Neurocrine Biosciences
- Class 3-ring heterocyclic compounds; Amino acids; Antipsychotics; Neuropsychotherapeutics; Small molecules
- Mechanism of Action Vesicular monoamine transporter 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chorea; Drug-induced dyskinesia
- Phase III Cerebral palsy; Schizophrenia
- Phase II Gilles de la Tourette's syndrome
Most Recent Events
- 01 Mar 2024 Neurocrine Biosciences initiates phase II trial in Chorea in Canada (PO) (NCT06312189)
- 15 Dec 2023 Neurocrine Biosciences terminates a phase-III trial in Schizophrenia (In adolescents, In adults, In the elderly, Adjunctive treatment) in USA (PO) due to business reasons(NCT05654870)
- 23 Nov 2023 Planned Prescription Drug User Fee Act (PDUFA) date for Chorea (In the elderly, In adults) in USA (PO) is 2023-08-20